Kiyoshi Hashigami
AstraZeneca
3 Papers
22 Citations
Kiyoshi Hashigami is an academic researcher from AstraZeneca. The author has contributed to research in topics: Clinical endpoint & Observational study. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.
Kamlesh Khunti,Thomas Godec,Jesús Medina,Laura Garcia‐Alvarez,Josh Hiller,Marília B. Gomes,Javier Cid-Ruzafa,Bernard Charbonnel,Peter Fenici,Niklas Hammar,Niklas Hammar,Kiyoshi Hashigami,Mikhail Kosiborod,Antonio Nicolucci,Marina Vladimirovna Shestakova,Linong Ji,Stuart J. Pocock +16 more
TL;DR: Determinants of change in glycated haemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM) at 6 months after initiating uninterrupted second‐line glucose‐lowering therapies are investigated.
47
Rationale and Design for the J-DISCOVER Study: DISCOVERing the Treatment Reality of Type 2 Diabetes in a Real-World Setting in Japan-A Protocol.
Naoto Katakami,Tomoya Mita,Mitsuyoshi Takahara,Kiyoshi Hashigami,Masaru Kawashima,Iichiro Shimomura,Hirotaka Watada +6 more
TL;DR: J-DISCOVER aims to address the lack of data on the management of type 2 diabetes mellitus by providing real-world data on disease management patterns and associated outcomes in a large number of Japanese T2DM patients who are initiating second-line therapy.
Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program.
Linong Ji,Fabrice Bonnet,Bernard Charbonnel,Marília B. Gomes,Mikhail Kosiborod,Kamlesh Khunti,Antonio Nicolucci,Stuart J. Pocock,Wolfgang Rathmann,Marina Vladimirovna Shestakova,Iichiro Shimomura,Hirotaka Watada,Peter Fenici,Niklas Hammar,Kiyoshi Hashigami,Greg Macaraeg,Filip Surmont,Jesús Medina +17 more
TL;DR: The global DISCOVER study program aims to describe the disease management patterns and a broad range of associated outcomes in patients with type 2 diabetes initiating a second-line glucose-lowering therapy in routine clinical practice, to contribute to informing future clinical guidelines and improving patient care.